trial
as of 2026-07-01Add On Treatment for Cognitive Deficits in Schizophrenia
NCTId NCT01346163
at a glance
Phase 1 · Completed
Enrollment 16 (actual)
Sponsored by University of Pennsylvania
Primary completion 2010-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2009-04
Primary completion
2010-11
Eligibility
ALL · 18 Years · 40 Years
Interventions & indications
Drugs
Sponsors
University of PennsylvaniaLead Sponsor
Investigators
1
Raquel P. Gur, M.D., Ph.D.Principal Investigator
Sites
1 total
Philadelphia, United States
Facts & assertions
4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2010-11
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
investigator